Skip to main content

Netherton Syndrome

7
Pipeline Programs
7
Companies
12
Clinical Trials
5 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
2
0
4
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

7 companies ranked by most advanced pipeline stage

Quoin Pharmaceuticals
4 programs
4
QRX003Phase 2/31 trial
QRX003, 4% LotionPhase 2/31 trial
QRX003, 4% LotionPhase 2/31 trial
QRX003-2% LotionPhase 2/31 trial
Active Trials
NCT07538583Recruiting16Est. Mar 2027
NCT05789056Recruiting20Est. Dec 2025
NCT06953466Recruiting8Est. Jul 2026
+1 more trials
Sandoz
SandozAustria - Kundl
1 program
1
Pimecrolimus 1% CreamPhase 1/2
Sixera Pharma
Sixera PharmaSweden - Stockholm
1 program
1
SXR1096 creamPhase 1/21 trial
Active Trials
NCT05211830Completed9Est. Aug 2025
Azitra
AzitraBRANFORD, CT
1 program
1
ATR12-351Phase 11 trial
Active Trials
NCT06137157Recruiting12Est. Aug 2026
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
2 programs
Natural History of Netherton SyndromeN/A1 trial
Spesolimab - solution for infusionPHASE_2_31 trial
Active Trials
NCT05902663Terminated12Est. Mar 2025
NCT05856526Terminated43Est. Jul 2025
BioCryst Pharmaceuticals
1 program
BCX17725PHASE_11 trial
Active Trials
NCT06539507Recruiting78Est. Dec 2026
Daiichi Sankyo
Daiichi SankyoChina - Shanghai
1 program
DS-2325aPHASE_1_23 trials
Active Trials
NCT05979831Terminated9Est. Jan 2025
NCT05583669Completed24Est. May 2023
NCT05388903Completed64Est. Jan 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Quoin PharmaceuticalsQRX003
Quoin PharmaceuticalsQRX003, 4% Lotion
Boehringer IngelheimSpesolimab - solution for infusion
Quoin PharmaceuticalsQRX003, 4% Lotion
Quoin PharmaceuticalsQRX003-2% Lotion
Daiichi SankyoDS-2325a
Sixera PharmaSXR1096 cream
BioCryst PharmaceuticalsBCX17725
AzitraATR12-351
Daiichi SankyoDS-2325a
Daiichi SankyoDS-2325a
Boehringer IngelheimNatural History of Netherton Syndrome

Clinical Trials (12)

Total enrollment: 325 patients across 12 trials

Phase 2/3 Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome

Start: Mar 2026Est. completion: Mar 202716 patients
Phase 2/3Recruiting

Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome

Start: Jul 2025Est. completion: Jul 20268 patients
Phase 2/3Recruiting
NCT05856526Boehringer IngelheimSpesolimab - solution for infusion

A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Netherton Syndrome

Start: Jun 2023Est. completion: Jul 202543 patients
Phase 2/3Terminated

Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome

Start: Mar 2023Est. completion: Dec 202520 patients
Phase 2/3Recruiting

Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome

Start: Jun 2022Est. completion: Dec 202630 patients
Phase 2/3Active Not Recruiting

A Study to Explore Safety, Pharmacokinetics, and Early Clinical Signal of Efficacy of DS-2325a in Patients With Netherton Syndrome

Start: Sep 2023Est. completion: Jan 20259 patients
Phase 1/2Terminated

A Study to Evaluate Topically Applied SXR1096 Cream in Patients With Netherton Syndrome

Start: Dec 2021Est. completion: Aug 20259 patients
Phase 1/2Completed

A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725

Start: Sep 2024Est. completion: Dec 202678 patients
Phase 1Recruiting

Evaluation of Topical ATR12-351 in Adults With Netherton Syndrome

Start: Jun 2024Est. completion: Aug 202612 patients
Phase 1Recruiting

A Study to Assess the Safety and Pharmacokinetics of Multiple Ascending Subcutaneous Doses of DS-2325a in Healthy Subjects

Start: Nov 2022Est. completion: May 202324 patients
Phase 1Completed

A Study to Assess the Safety and Pharmacokinetics of Single Ascending Subcutaneous and Intravenous Doses of DS-2325a in Healthy Subjects

Start: Jun 2022Est. completion: Jan 202364 patients
Phase 1Completed
NCT05902663Boehringer IngelheimNatural History of Netherton Syndrome

Natural History of Netherton Syndrome

Start: Oct 2024Est. completion: Mar 202512 patients
N/ATerminated

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

5 actively recruiting trials targeting 325 patients
7 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.